Jeffrey del Carmen - 09 Aug 2024 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Commercial Officer
Signature
/s/ Jeffrey Del Carmen
Issuer symbol
CPRX
Transactions as of
09 Aug 2024
Net transactions value
-$578,510
Form type
4
Filing time
13 Aug 2024, 17:01:29 UTC
Previous filing
11 Jun 2024
Next filing
25 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Sale $111,710 -6,058 -33% $18.44 12,369 09 Aug 2024 Direct F1
transaction CPRX Common stock, par value $0.001 per share Options Exercise $85,800 +30,000 +243% $2.86 42,369 09 Aug 2024 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $552,600 -30,000 -71% $18.42 12,369 09 Aug 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -30,000 -3.6% $0.000000 804,019 09 Aug 2024 Common Stock 30,000 $2.86 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
F2 Shares were sold in various lots from $18.33 to $18.48 per share. The price listed represents a weighted average price for the shares sold.
F3 Shares vested in five annual tranches beginning on August 6, 2019.